Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

January’s top stories: Bristol-Myers stops Opdivo trial, Boehringer COPD study

Bristol-Myers Squibb (BMS) stopped its open-label, randomised Phase III trial (CheckMate -017) evaluating Opdivo versus docetaxel, Boehringer started patient enrolment in its Dynagito study to treat COPD, while Medivation and Astellas report positive results from Phase II TERRAIN trial for prostate cancer. Drugdevelopment-technology.com wraps-up key headlines from January.

Go Top